Product Description
Mechanisms of Action: 5-HT2A Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United Kingdom
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2071250071 |
jRCT2071250071 | P1 |
Recruiting |
Depressive Disorder, Major |
2026-05-31 |
|||
NCT07329621 |
NCT07329621 | P1 |
Recruiting |
Depressive Disorder, Major |
2027-01-29 |
12% |
2026-06-17 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/28/2023 |
News Article |
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics |
|
11/30/2022 |
News Article |
Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders |
|
10/05/2022 |
News Article |
Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio |